D.E. Shaw & Co
FOLD

D.E. Shaw & Co’s Amicus Therapeutics FOLD Stock Holding History

D.E. Shaw & Co’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.06M Sell
488,098
-1,060,905
-68% -$15.2M ﹤0.01% 1914
2025
Q4 		$22.1M Sell
1,549,003
-2,319,207
-60% -$22.8M 0.01% 1192
2025
Q3 		$30.5M Sell
3,868,210
-2,494,040
-39% -$17.7M 0.02% 911
2025
Q2 		$36.5M Buy
6,362,250
+4,071,968
+178% +$26.3M 0.03% 718
2025
Q1 		$18.7M Buy
2,290,282
+729,872
+47% +$6.75M 0.02% 986
2024
Q4 		$14.7M Buy
1,560,410
+889,968
+133% +$9.25M 0.01% 1237
2024
Q3 		$7.16M Buy
670,442
+581,167
+651% +$6.33M 0.01% 1667
2024
Q2 		$886K Sell
89,275
-35,751
-29% -$367K ﹤0.01% 3271
2024
Q1 		$1.47M Sell
125,026
-161,198
-56% -$2.06M ﹤0.01% 2840
2023
Q4 		$4.06M Sell
286,224
-73,967
-21% -$840K ﹤0.01% 2077
2023
Q3 		$4.38M Sell
360,191
-771,735
-68% -$9.96M ﹤0.01% 1922
2023
Q2 		$14.2M Sell
1,131,926
-519,671
-31% -$6.17M 0.01% 1088
2023
Q1 		$18.3M Sell
1,651,597
-581,728
-26% -$7.17M 0.02% 953
2022
Q4 		$27.3M Sell
2,233,325
-670,171
-23% -$7.54M 0.03% 721
2022
Q3 		$30.3M Sell
2,903,496
-65,240
-2% -$727K 0.04% 623
2022
Q2 		$31.9M Sell
2,968,736
-75,702
-2% -$623K 0.04% 615
2022
Q1 		$28.8M Buy
3,044,438
+279,142
+10% +$2.62M 0.03% 795
2021
Q4 		$31.9M Buy
2,765,296
+573,279
+26% +$6.39M 0.03% 791
2021
Q3 		$20.9M Sell
2,192,017
-766,130
-26% -$7.84M 0.02% 993
2021
Q2 		$28.5M Sell
2,958,147
-1,456,829
-33% -$14.2M 0.02% 820
2021
Q1 		$43.6M Sell
4,414,976
-2,664,620
-38% -$41.2M 0.04% 546
2020
Q4 		$163M Sell
7,079,596
-264,668
-4% -$5.41M 0.15% 137
2020
Q3 		$104M Buy
7,344,264
+296,215
+4% +$4.32M 0.11% 211
2020
Q2 		$106M Buy
7,048,049
+1,482,310
+27% +$18.1M 0.13% 160
2020
Q1 		$51.4M Buy
5,565,739
+1,739,698
+45% +$16.5M 0.08% 283
2019
Q4 		$37.3M Buy
3,826,041
+1,034,197
+37% +$9.47M 0.04% 517
2019
Q3 		$22.4M Buy
2,791,844
+644,441
+30% +$6.99M 0.03% 721
2019
Q2 		$26.8M Buy
2,147,403
+1,146,777
+115% +$14.6M 0.03% 612
2019
Q1 		$13.6M Buy
1,000,626
+109,646
+12% +$1.34M 0.02% 921
2018
Q4 		$8.54M Sell
890,980
-1,509,694
-63% -$16.6M 0.01% 1188
2018
Q3 		$29M Sell
2,400,674
-1,324,370
-36% -$18.5M 0.03% 605
2018
Q2 		$58.2M Sell
3,725,044
-694,735
-16% -$10.5M 0.08% 323
2018
Q1 		$66.5M Buy
4,419,779
+1,963,566
+80% +$29.9M 0.09% 271
2017
Q4 		$35.3M Sell
2,456,213
-2,049,287
-45% -$28.2M 0.05% 449
2017
Q3 		$67.9M Buy
4,505,500
+435,205
+11% +$5.76M 0.1% 239
2017
Q2 		$41M Buy
4,070,295
+488,357
+14% +$3.93M 0.07% 343
2017
Q1 		$25.5M Buy
3,581,938
+1,251,339
+54% +$7.91M 0.04% 479
2016
Q4 		$11.6M Buy
2,330,599
+31,528
+1% +$218K 0.02% 873
2016
Q3 		$17M Sell
2,299,071
-476,522
-17% -$3.22M 0.03% 645
2016
Q2 		$15.2M Sell
2,775,593
-127,879
-4% -$894K 0.03% 655
2016
Q1 		$24.5M Sell
2,903,472
-522,024
-15% -$3.7M 0.04% 463
2015
Q4 		$33.2M Buy
3,425,496
+2,030,981
+146% +$18.3M 0.05% 428
2015
Q3 		$19.5M Sell
1,394,515
-236,209
-14% -$3.7M 0.03% 627
2015
Q2 		$23.1M Sell
1,630,724
-938,602
-37% -$11.3M 0.03% 588
2015
Q1 		$28M Sell
2,569,326
-486,838
-16% -$4.29M 0.04% 492
2014
Q4 		$25.4M Buy
3,056,164
+1,550,432
+103% +$10.6M 0.03% 605
2014
Q3 		$8.96M Buy
1,505,732
+921,150
+158% +$4.83M 0.01% 1158
2014
Q2 		$1.95M Sell
584,582
-76,208
-12% -$179K ﹤0.01% 2324
2014
Q1 		$1.37M Buy
660,790
+53,742
+9% +$134K ﹤0.01% 2760
2013
Q4 		$1.43M Buy
607,048
+187,355
+45% +$411K ﹤0.01% 2846
2013
Q3 		$974K Buy
419,693
+48,832
+13% +$123K ﹤0.01% 3063
2013
Q2 		$864K Buy
+370,861
New +$1.14M ﹤0.01% 2838

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

D.E. Shaw & Co's FOLD Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Amicus Therapeutics (FOLD) stake by 68% in Q1 2026, selling an estimated $15.2M and leaving 488,098 shares worth $7.06M. The position accounts for ﹤0.01% of the portfolio, ranked #1914.

D.E. Shaw & Co first reported a position in FOLD in Q2 2013 and has held it in 52 quarters since. The position peaked at $163M in Q4 2020. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • D.E. Shaw & Co held 488,098 shares of Amicus Therapeutics worth $7.06M as of Q1 2026.
  • D.E. Shaw & Co sold 1,060,905 Amicus Therapeutics shares in Q1 2026, an estimated $15.2M.
  • Amicus Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #1914 holding.
  • D.E. Shaw & Co first reported a position in Amicus Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • D.E. Shaw & Co's Amicus Therapeutics position peaked at $163M in Q4 2020.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.